Alpha 2.0
Login Register
» Authors » Ahmad Rajeh

Ahmad Rajeh

Explore the profile of Ahmad Rajeh including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 113
Followers 0
Related Specialties
Dermatology
General Medicine
Infectious Diseases
Top 10 Co-Authors
Yevgeniy R Semenov
Guihong Wan
Nga Nguyen
Shawn G Kwatra
Katie Roster
Hannah Rashdan
Alexander Gusev
Kun-Hsing Yu
Bonnie W Leung
Nicole R LeBoeuf
Published In
J Am Acad Dermatol
J Eur Acad Dermatol Venereol
Br J Dermatol
Clin Transl Med
JAMA Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Seasonal and geographic variation in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors
Rajeh A, Roster K, Reynolds K, LeBoeuf N, Sullivan R, Kwatra S, et al.
J Eur Acad Dermatol Venereol . 2024 Dec; PMID: 39707682
No abstract available.
2.
A retrospective cohort study of the time between prior antibiotics and checkpoint inhibitors and association with survival in melanoma patients
Hirner J, Rajeh A, Semenov Y, Kwatra S, LeBoeuf N
J Am Acad Dermatol . 2024 Nov; PMID: 39549842
No abstract available.
3.
Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma
de Almeida N, Janosi A, Hong R, Rajeh A, Nogueira F, Szadai L, et al.
Clin Transl Med . 2024 Jul; 14(7):e1773. PMID: 39032005
No abstract available.
4.
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
Wan G, Chen W, Khattab S, Roster K, Nguyen N, Yan B, et al.
Lancet Oncol . 2024 Jul; 25(8):1053-1069. PMID: 39025103
Background: Understanding co-occurrence patterns and prognostic implications of immune-related adverse events is crucial for immunotherapy management. However, previous studies have been limited by sample size and generalisability. In this study,...
5.
Surgical margin reduction in excision of cutaneous melanoma: A retrospective analysis
Rajeh A, Roster K, Nguyen N, Leung B, Rashdan H, Semenov Y
J Eur Acad Dermatol Venereol . 2024 Jul; 39(3):e225-e227. PMID: 38953368
No abstract available.
6.
De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study
Tang K, Rajeh A, Shaw K, Nguyen N, Wan G, Hashemi K, et al.
Br J Dermatol . 2024 Apr; 191(3):460-462. PMID: 38676955
No abstract available.
7.
Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation
Cornman H, Manjunath J, Reddy S, Adams J, Rajeh A, Samuel C, et al.
Sci Rep . 2024 Apr; 14(1):8098. PMID: 38582943
Prurigo nodularis (PN) is a chronic inflammatory skin disease that is associated with variability in peripheral blood eosinophil levels and response to T-helper 2 targeted therapies (Th2). Our objective was...
8.
Radiation Recall Dermatitis With Bruton Tyrosine Kinase Inhibitor Therapy
Rajeh A, Ferree S, Anadkat M
JAMA Dermatol . 2024 Mar; 160(5):577-578. PMID: 38536185
No abstract available.
9.
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study
Wan G, Khattab S, Leung B, Zhang S, Nguyen N, Tran M, et al.
Br J Dermatol . 2024 Feb; 191(1):117-124. PMID: 38366637
Background: Cutaneous immune-related adverse events (cirAEs) are the most common toxicities to occur in the setting of immune checkpoint inhibitor (ICI) therapy. Identifying patients who are at increased risk of...
10.
Specialty Utilization Disparities Among Hidradenitis Suppurativa Patients in a Retrospective Analysis of the National Ambulatory Medical Care Survey 2006-2016
Roster K, Rajeh A, Lipner S
Dermatol Pract Concept . 2024 Feb; 14(1). PMID: 38364409
No abstract available.